Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities (original) (raw)

• Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75, 333–366 (2006).
  Article CAS PubMed Google Scholar
• Herczenik, E. & Gebbink, M. F. B. G. Molecular and cellular aspects of protein misfolding and disease. FASEB J 22, 2115–2133, doi:10.1096/fj.07-099671 (2008).
  Article CAS PubMed Google Scholar
• Rambaran, R. N. & Serpell, L. C. Amyloid fibrils: abnormal protein assembly. Prion 2, 112–117 (2008).
  Article PubMed PubMed Central Google Scholar
• Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–1203, doi:10.1016/j.cell.2012.02.022 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Knowles, T. P. J., Vendruscolo, M. & Dobson, C. M. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15, 384–396, doi:10.1038/nrm3810 (2014).
  Article CAS PubMed Google Scholar
• Tipping, K. W., van Oosten-Hawle, P., Hewitt, E. W. & Radford, S. E. Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease? Trends Biochem Sci 40, 719–727, doi:10.1016/j.tibs.2015.10.002 (2015).
  Article CAS PubMed Google Scholar
• Sipe, J. D. et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21, 221–224, doi:10.3109/13506129.2014.964858 (2014).
  Article PubMed Google Scholar
• Olanow, C. W. & Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 28, 31–40, doi:10.1002/mds.25373 (2013).
  Article CAS PubMed Google Scholar
• Uversky, V. N., Li, J. & Fink, A. L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem 276, 44284–44296 (2001).
  Article CAS PubMed Google Scholar
• Vilar, M. et al. The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A 105, 8637–8642, doi:10.1073/pnas.0712179105 (2008).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Fändrich, M., Meinhardt, J. & Grigorieff, N. Structural polymorphism of Alzheimer Abeta and other amyloid fibrils. Prion 3, 89–93 (2009).
  Article PubMed PubMed Central Google Scholar
• Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307, 262–265, doi:10.1126/science.1105850 (2005).
  Article ADS CAS PubMed Google Scholar
• Serpell, L. C. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 1502, 16–30 (2000).
  Article CAS PubMed Google Scholar
• Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536, 41–47, doi:10.1038/nature18642 (2016).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Cooper, G. J. S. et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84, 8628–8632 (1987).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Cooper, G. J. S. et al. Amylin Found in Amyloid Deposits in Human Type-2 Diabetes-Mellitus May Be a Hormone That Regulates Glycogen-Metabolism in Skeletal-Muscle. Proc Natl Acad Sci 85, 7763–7766, doi:10.1073/pnas.85.20.7763 (1988).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Lorenzo, A., Razzaboni, B., Weir, G. C. & Yankner, B. A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756–760, doi:10.1038/368756a0 (1994).
  Article ADS CAS PubMed Google Scholar
• Jaikaran, E. T. A. S. & Clark, A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 1537, 179–203 (2001).
  Article CAS PubMed Google Scholar
• Loomes, K. M. Survival of an islet beta-cell in type-2 diabetes: curbing the effects of amyloid cytotoxicity. Islets 3, 38–39 (2011).
  Article PubMed Google Scholar
• Höppener, J. W. M. & Lips, C. J. M. Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol 38, 726–736, doi:10.1016/j.biocel.2005.12.009 (2006).
  Article PubMed CAS Google Scholar
• Pillay, K. & Govender, P. Amylin uncovered: a review on the polypeptide responsible for type II diabetes. Biomed Res Int 2013, 826706, doi:10.1155/2013/826706 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Zhang, S. et al. The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet beta cells. FASEB J 28, 5083–5096, doi:10.1096/fj.14-251744 (2014).
  Article CAS PubMed Google Scholar
• Gurlo, T. et al. beta Cell-specific increased expression of calpastatin prevents diabetes induced by islet amyloid polypeptide toxicity. JCI Insight 1, e89590, doi:10.1172/jci.insight.89590 (2016).
  Article PubMed PubMed Central Google Scholar
• Janson, J., Ashley, R. H., Harrison, D., McIntyre, S. & Butler, P. C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491–498 (1999).
  Article CAS PubMed Google Scholar
• Daval, M. et al. The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity. Amyloid 17, 118–128, doi:10.3109/13506129.2010.530008 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Campbell, R. A., Aleman, M., Gray, L. D., Falvo, M. R. & Wolberg, A. S. Flow profoundly influences fibrin network structure: implications for fibrin formation and clot stability in haemostasis. Thromb Haemost 104, 1281–1284, doi:10.1160/TH10-07-0442 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Pretorius, E., Steyn, H., Engelbrecht, M., Swanepoel, A. C. & Oberholzer, H. M. Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients. Blood Coagul Fibrinolysis 22, 696–700, doi:10.1097/MBC.0b013e32834bdb32 (2011).
  Article PubMed Google Scholar
• Weigandt, K. M. et al. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen. Biophys J 103, 2399–2407, doi:10.1016/j.bpj.2012.10.036 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bester, J., Soma, P., Kell, D. B. & Pretorius, E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget Gerontology 6, 35284–35303 (2015).
  Google Scholar
• Kell, D. B. & Pretorius, E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr Biol 7, 24–52, doi:10.1039/c4ib00173g (2015).
  Article CAS Google Scholar
• Alzahrani, S. H. & Ajjan, R. A. Coagulation and fibrinolysis in diabetes. Diabet Vasc Dis Res 7, 260–273, doi:10.1177/1479164110383723 (2010).
  Article CAS Google Scholar
• Pretorius, E., Oberholzer, H. M., van der Spuy, W. J., Swanepoel, A. C. & Soma, P. Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes. Blood Coagul Fibrinol 22, 463–467, doi:10.1097/MBC.0b013e3283468a0d (2011).
  Article CAS Google Scholar
• Pretorius, E. et al. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol 13, 30 (2015).
  Article CAS Google Scholar
• Jörneskog, G. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39, 1519–1523 (1996).
  Article PubMed Google Scholar
• Dunn, E. J. & Ariëns, R. A. S. Fibrinogen and fibrin clot structure in diabetes. Herz 29, 470–479, doi:10.1007/s00059-004-2607-z (2004).
  Article PubMed Google Scholar
• Dunn, E. J., Ariëns, R. A. S. & Grant, P. J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48, 1198–1206, doi:10.1007/s00125-005-1742-2 (2005).
  Article CAS PubMed Google Scholar
• Dunn, E. J., Philippou, H., Ariëns, R. A. S. & Grant, P. J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49, 1071–1080, doi:10.1007/s00125-006-0197-4 (2006).
  Article CAS PubMed Google Scholar
• Pieters, M. et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 96, 623–629 (2006).
  CAS PubMed Google Scholar
• Alzahrani, S. H. et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 97, E2282–2287, doi:10.1210/jc.2012-2128 (2012).
  Article CAS PubMed Google Scholar
• Weisel, J. W. Fibrinogen and fibrin. Adv Protein Chem 70, 247–299, doi:10.1016/s0065-3233(05)70008-5 (2005).
  Article CAS PubMed Google Scholar
• Wolberg, A. S. Thrombin generation and fibrin clot structure. Blood Rev 21, 131–142, doi:10.1016/j.blre.2006.11.001 (2007).
  Article CAS PubMed Google Scholar
• C L Corte, A. L., Philippou, H. & Ariëns, R. A. S. Role of fibrin structure in thrombosis and vascular disease. Adv Protein Chem Struct Biol 83, 75–127, doi:10.1016/B978-0-12-381262-9.00003-3 (2011).
  Article CAS Google Scholar
• Undas, A. & Ariëns, R. A. S. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31, e88–99, doi:10.1161/ATVBAHA.111.230631 (2011).
  Article CAS PubMed Google Scholar
• Wolberg, A. S. Determinants of fibrin formation, structure, and function. Curr Opin Hematol 19, 349–356, doi:10.1097/MOH.0b013e32835673c2 (2012).
  Article CAS PubMed Google Scholar
• Averett, L. E. et al. Complexity of "A-a" knob-hole fibrin interaction revealed by atomic force spectroscopy. Langmuir 24, 4979–4988, doi:10.1021/la703264x (2008).
  Article CAS PubMed Google Scholar
• Yermolenko, I. S., Lishko, V. K., Ugarova, T. P. & Magonov, S. N. High-resolution visualization of fibrinogen molecules and fibrin fibers with atomic force microscopy. Biomacromolecules 12, 370–379, doi:10.1021/bm101122g (2011).
  Article CAS PubMed Google Scholar
• Protopopova, A. D. et al. Visualization of fibrinogen alphaC regions and their arrangement during fibrin network formation by high-resolution AFM. J Thromb Haemost 13, 570–579, doi:10.1111/jth.12785 (2015).
  Article CAS PubMed Google Scholar
• Kell, D. B. & Pretorius, E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progr Biophys Mol Biol 123, 16–41, doi:10.1016/j.pbiomolbio.2016.08.006 (2017).
  Article CAS Google Scholar
• Dickneite, G. et al. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost 113, 686–697, doi:10.1160/TH14-07-0625 (2015).
  Article PubMed Google Scholar
• Maji, S. K., Wang, L., Greenwald, J. & Riek, R. Structure-activity relationship of amyloid fibrils. FEBS Lett 583, 2610–2617, doi:10.1016/j.febslet.2009.07.003 (2009).
  Article CAS PubMed Google Scholar
• Morris, K. L. & Serpell, L. C. X-ray fibre diffraction studies of amyloid fibrils. Methods Mol Biol 849, 121–135, doi:10.1007/978-1-61779-551-0_9 (2012).
  Article CAS PubMed Google Scholar
• Tycko, R. & Wickner, R. B. Molecular structures of amyloid and prion fibrils: consensus versus controversy. Acc Chem Res 46, 1487–1496, doi:10.1021/ar300282r (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Langkilde, A. E., Morris, K. L., Serpell, L. C., Svergun, D. I. & Vestergaard, B. The architecture of amyloid-like peptide fibrils revealed by X-ray scattering, diffraction and electron microscopy. Acta Crystallogr D Biol Crystallogr 71, 882–895, doi:10.1107/S1399004715001674 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• LeVine, H. 3rd Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309, 274–284 (1999).
  Article CAS PubMed Google Scholar
• Biancalana, M., Makabe, K., Koide, A. & Koide, S. Molecular mechanism of thioflavin-T binding to the surface of beta-rich peptide self-assemblies. J Mol Biol 385, 1052–1063, doi:10.1016/j.jmb.2008.11.006 (2009).
  Article CAS PubMed Google Scholar
• Biancalana, M. & Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 1804, 1405–1412, doi:10.1016/j.bbapap.2010.04.001 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Groenning, M. Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J Chem Biol 3, 1–18, doi:10.1007/s12154-009-0027-5 (2010).
  Article PubMed Google Scholar
• Sulatskaya, A. I., Kuznetsova, I. M. & Turoverov, K. K. Interaction of thioflavin T with amyloid fibrils: stoichiometry and affinity of dye binding, absorption spectra of bound dye. J Phys Chem B 115, 11519–11524, doi:10.1021/jp207118x (2011).
  Article CAS PubMed Google Scholar
• Freire, S., de Araujo, M. H., Al-Soufi, W. & Novo, M. Photophysical study of Thioflavin T as fluorescence marker of amyloid fibrils. Dyes and Pigments 110, 97–105, doi:10.1016/j.dyepig.2014.05.004 (2014).
  Article CAS Google Scholar
• Serpell, L. C., Benson, M., Liepnieks, J. J. & Fraser, P. E. Structural analyses of fibrinogen amyloid fibrils. Amyloid 14, 199–203, doi:10.1080/13506120701461111 (2007).
  Article CAS PubMed Google Scholar
• Picken, M. M. Fibrinogen amyloidosis: the clot thickens! Blood 115, 2985–2986, doi:10.1182/blood-2009-12-236810 (2010).
  Article CAS PubMed Google Scholar
• Stangou, A. J. et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115, 2998–3007, doi:10.1182/blood-2009-06-223792 (2010).
  Article CAS PubMed Google Scholar
• Haidinger, M. et al. Hereditary amyloidosis caused by R554L fibrinogen Aalpha-chain mutation in a Spanish family and review of the literature. Amyloid 20, 72–79, doi:10.3109/13506129.2013.781998 (2013).
  Article CAS PubMed Google Scholar
• Kell, D. B. & Pretorius, E. Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells. Metallomics 6, 748–773, doi:10.1039/C3MT00347G (2014).
  Article CAS PubMed Google Scholar
• Pretorius, E., Vermeulen, N., Bester, J., Lipinski, B. & Kell, D. B. A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. Toxicol Mech Methods 23, 352–359, doi:10.3109/15376516.2012.762082 (2013).
  Article CAS PubMed Google Scholar
• Pretorius, E. et al. Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents. PLoS One 9, e85271 (2014).
  Article ADS PubMed PubMed Central CAS Google Scholar
• Pretorius, E. & Kell, D. B. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integrative Biol 6, 486–510 (2014).
  Article CAS Google Scholar
• Pretorius, E., Mbotwe, S., Bester, J., Robinson, C. J. & Kell, D. B. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface 123, 20160539, doi:10.1098/rsif.2016.0539 (2016).
  Article Google Scholar
• Pretorius, E., Mbotwe, S., Bester, J., Robinson, C. & Kell, D. B. Acute induction of anomalous blood clotting by highly substoichiometric levels of bacterial lipopolysaccharide (LPS). bioRxiv, 2016-053538v053531, doi:10.1101/053538 (2016).
• Kell, D. B. & Pretorius, E. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. bioRxiv preprint. bioRxiv, 054734, doi:10.1101/054734 (2016).
• Potgieter, M., Bester, J., Kell, D. B. & Pretorius, E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev 39, 567–591, doi:10.1093/femsre/fuv013 (2015).
  Article PubMed PubMed Central Google Scholar
• Kell, D. B., Potgieter, M. & Pretorius, E. Individuality, phenotypic differentiation, dormancy and ‘persistence’ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research 4, 179, doi:10.12688/f1000research.6709.1 (2015).
  PubMed PubMed Central Google Scholar
• Kell, D. B. & Pretorius, E. On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biol 7, 1339–1377, doi:10.1039/C5IB00158G (2015).
  Article CAS Google Scholar
• Itzhaki, R. F. et al. Microbes and Alzheimer's Disease. J Alzheimers Dis 51, 979–984, doi:10.3233/JAD-160152 (2016).
  Article PubMed PubMed Central Google Scholar
• Kell, D. B. & Kenny, L. C. A dormant microbial component in the development of pre-eclampsia. BioRxiv preprint. bioRxiv, 057356 (2016).
• Kell, D. B. & Pretorius, E. To what extent are the terminal stages of sepsis, septic shock, SIRS, and multiple organ dysfunction syndrome actually driven by a toxic prion/amyloid form of fibrin? bioRxiv preprint. bioRxiv, 057851, doi:10.1101/057851 (2016).
• Pretorius, E., Akeredolu, O.-O., Soma, P. & Kell, D. B. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp Biol Med, in press (2016).
• Pretorius, E., Bester, J. & Kell, D. B. A bacterial component to Alzheimer-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis 53, 1237–1256 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Kell, D. B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2, 2 (2008).
  Article CAS Google Scholar
• Kell, D. B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 577, 825–889, doi:10.1007/s00204-010-0577-x (2010).
  Article CAS Google Scholar
• Al-Attas, O. S. et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 8, 20, doi:10.1186/1475-2840-8-20 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Hawkesworth, S. et al. Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes 3, e83, doi:10.1038/nutd.2013.24 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Zaman, G. S. & Zaman, F. Relationship between postprandial endotoxemia in nonobese postmenopausal women and diabetic nonobese postmenopausal women. J Nat Sci Biol Med 6, 89–93, doi:10.4103/0976-9668.149098 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Liang, H., Hussey, S. E., Sanchez-Avila, A., Tantiwong, P. & Musi, N. Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 8, e63983, doi:10.1371/journal.pone.0063983 (2013).
  Article ADS PubMed PubMed Central Google Scholar
• Lipinski, B., Pretorius, E., Oberholzer, H. M. & Van Der Spuy, W. J. Iron enhances generation of fibrin fibers in human blood: Implications for pathogenesis of stroke. Microsc Res Tech 75, 1185–1190, doi:10.1002/jemt.22047 (2012).
  Article CAS PubMed Google Scholar
• Lassenius, M. I. et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 34, 1809–1815, doi:10.2337/dc10-2197 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Nymark, M. et al. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care 32, 1689–1693, doi:10.2337/dc09-0467 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carr, M. E. Diabetes mellitus: a hypercoagulable state. J Diabet Complic 15, 44–54 (2001).
  Article CAS Google Scholar
• Banga, J. D. Coagulation and fibrinolysis in diabetes. Semin Vasc Med 2, 75–86, doi:10.1055/s-2002-23098 (2002).
  Article CAS PubMed Google Scholar
• Thor, M., Yu, A. & Swedenborg, J. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thromb Res 105, 379–383 (2002).
  Article CAS PubMed Google Scholar
• Aras, R., Sowers, J. R. & Arora, R. The proinflammatory and hypercoagulable state of diabetes mellitus. Rev Cardiovasc Med 6, 84–97 (2005).
  PubMed Google Scholar
• Grant, P. J. Diabetes mellitus as a prothrombotic condition. J Intern Med 262, 157–172, doi:10.1111/j.1365-2796.2007.01824.x (2007).
  Article ADS CAS PubMed Google Scholar
• Tripodi, A. et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 31, 165–172, doi:10.1007/s11239-010-0506-0 (2011).
  Article CAS PubMed Google Scholar
• Ye, Y., Perez-Polo, J. R., Aguilar, D. & Birnbaum, Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 106, 925–952, doi:10.1007/s00395-011-0216-6 (2011).
  Article CAS PubMed Google Scholar
• Beijers, H. J. B. H. et al. Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation–the Hoorn Study. Thromb Res 129, 557–562, doi:10.1016/j.thromres.2011.07.033 (2012).
  Article CAS PubMed Google Scholar
• Cucuianu, M., Fekete, T., Marcusiu, C., Mosler, R. & Dutu, A. Fibrinolysis in diabetes mellitus. Role of overweight and hypertriglyceridemia. Medecine interne 22, 171–177 (1984).
  CAS PubMed Google Scholar
• Yano, Y. et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. The Journal of clinical endocrinology and metabolism 88, 736–741, doi:10.1210/jc.2002-020691 (2003).
  Article CAS PubMed Google Scholar
• Hess, K. et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 55, 1103–1113, doi:10.1007/s00125-011-2301-7 (2012).
  Article CAS PubMed Google Scholar
• Walus-Miarka, M. et al. Altered fibrin-clot properties are associated with retinopathy in type 2 diabetes mellitus. Diabetes & Metabolism 38, 462–465, doi:10.1016/j.diabet.2012.03.007 (2012).
  Article CAS Google Scholar
• Bochenek, M., Zalewski, J., Sadowski, J. & Undas, A. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis 35, 264–270, doi:10.1007/s11239-012-0821-8 (2013).
  Article CAS PubMed Google Scholar
• Konieczynska, M., Fil, K., Bazanek, M. & Undas, A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost 111, 685–693, doi:10.1160/th13-07-0566 (2014).
  Article CAS PubMed Google Scholar
• Pearson, F. C. et al. Comparison of several control standard endotoxins to the National Reference Standard Endotoxin–an HIMA collaborative study. Appl Environ Microbiol 50, 91–93 (1985).
  CAS PubMed PubMed Central Google Scholar
• Andrä, J. et al. Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide. Eur J Biochem 271, 2037–2046, doi:10.1111/j.1432-1033.2004.04134.x (2004).
  Article PubMed CAS Google Scholar
• Ketchum, P. A. & Novitsky, T. J. Assay of endotoxin by limulus amebocyte lysate. Methods Mol Med 36, 3–12, doi:10.1385/1-59259-216-3:3 (2000).
  CAS PubMed Google Scholar
• Mattsby-Baltzer, I., Lindgren, K., Lindholm, B. & Edebo, L. Endotoxin shedding by enterobacteria: free and cell-bound endotoxin differ in Limulus activity. Infect Immun 59, 689–695 (1991).
  CAS PubMed PubMed Central Google Scholar
• Novitsky, T. J. Limitations of the Limulus amebocyte lysate test in demonstrating circulating lipopolysaccharides. Ann N Y Acad Sci 851, 416–421 (1998).
  Article ADS CAS PubMed Google Scholar
• Novitsky, T. J. Biomedical Applications of Limulus Amebocyte Lysate. Biology and Conservation of Horseshoe Crabs, 315–329, doi:10.1007/978-0-387-89959-6_20 (2009).
• Brownlee, M., Vlassara, H. & Cerami, A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32, 680–684 (1983).
  Article CAS PubMed Google Scholar
• Pieters, M. et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost 99, 691–700, doi:10.1160/TH07-11-0699 (2008).
  CAS PubMed PubMed Central Google Scholar
• Howard, S. C., Algra, A. & Rothwell, P. M. Effect of age and glycaemic control on the association between fibrinogen and risk of acute coronary events after transient ischaemic attack or stroke. Cerebrovasc Dis 25, 136–143, doi:10.1159/000112324 (2008).
  Article CAS PubMed Google Scholar
• Svensson, J. et al. Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun 421, 335–342, doi:10.1016/j.bbrc.2012.03.154 (2012).
  Article CAS PubMed Google Scholar
• Fan, N. K., Keegan, P. M., Platt, M. O. & Averett, R. D. Experimental and imaging techniques for examining fibrin clot structures in normal and diseased states. J Vis Exp, e52019, doi:10.3791/52019 (2015).
• Bembde, A. S. A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control. Indian J Hematol Blood Transfus 28, 105–108, doi:10.1007/s12288-011-0116-9 (2012).
  Article PubMed Google Scholar
• McBane, R. D. 2nd, Hardison, R. M. & Sobel, B. E. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). Am J Cardiol 105, 17–24, doi:10.1016/j.amjcard.2009.08.643 (2010).
  Article CAS PubMed Google Scholar
• Ariëns, R. A. S. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 11(Suppl 1), 294–305, doi:10.1111/jth.12229 (2013).
  Article PubMed Google Scholar
• Soma, P. & Pretorius, E. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus. Cardiovasc Diabetol 14, 96, doi:10.1186/s12933-015-0261-9 (2015).
  Article PubMed PubMed Central Google Scholar
• Mayhew, T. M. & Sampson, C. Maternal diabetes mellitus is associated with altered deposition of fibrin-type fibrinoid at the villous surface in term placentae. Placenta 24, 524–531 (2003).
  Article CAS PubMed Google Scholar
• Cooper, G. J. S. et al. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochim Biophys Acta 1014, 247–258 (1989).
  Article CAS PubMed Google Scholar
• Marzban, L., Park, K. & Verchere, C. B. Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 38, 347–351 (2003).
  Article CAS PubMed Google Scholar
• Miklossy, J. et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31, 1503–1515, doi:10.1016/j.neurobiolaging.2008.08.019 (2010).
  Article CAS PubMed Google Scholar
• Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91, 795–826, doi:10.1152/physrev.00042.2009 (2011).
  Article CAS PubMed Google Scholar
• Westermark, G. T. & Westermark, P. Islet amyloid polypeptide and diabetes. Curr Protein Pept Sci 14, 330–337 (2013).
  Article CAS PubMed Google Scholar
• Díez, R., Madero, M., Gamba, G., Soriano, J. & Soto, V. Renal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus. Nephron Extra 4, 119–126, doi:10.1159/000363625 (2014).
  Article PubMed PubMed Central Google Scholar
• Anderberg, R. J. et al. Serum amyloid A and inflammation in diabetic kidney disease and podocytes. Lab Invest 95, 250–262, doi:10.1038/labinvest.2014.163 (2015).
  Article CAS PubMed Google Scholar
• Dieter, B. P. et al. Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. J Diabetes Complications, doi:10.1016/j.jdiacomp.2016.07.018 (2016).
• Kumon, Y., Suehiro, T., Itahara, T., Ikeda, Y. & Hashimoto, K. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem 27, 469–473 (1994).
  Article CAS PubMed Google Scholar
• Eren, M. A. et al. Association of serum amyloid A with subclinical atherosclerosis in women with gestational diabetes. Gynecol Endocrinol 28, 1010–1013, doi:10.3109/09513590.2012.705371 (2012).
  Article CAS PubMed Google Scholar
• Marzi, C. et al. Acute-phase serum amyloid A protein and its implication in the development of type 2 diabetes in the KORA S4/F4 study. Diabetes Care 36, 1321–1326, doi:10.2337/dc12-1514 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Reusch, J. E. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 112, 986–988 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Targher, G. et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212–1218 (2007).
  Article PubMed Google Scholar
• Singh, G. M. et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PloS one 8, e65174, doi:10.1371/journal.pone.0065174 (2013).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Basuli, D., Stevens, R. G., Torti, F. M. & Torti, S. V. Epidemiological associations between iron and cardiovascular disease and diabetes. Front Pharmacol 5, 117, doi:10.3389/fphar.2014.00117 (2014).
  PubMed PubMed Central Google Scholar
• Bertoni, A. G., Kramer, H., Watson, K. & Post, W. S. Diabetes and Clinical and Subclinical CVD. Glob Heart 11, 337–342, doi:10.1016/j.gheart.2016.07.005 (2016).
  Article PubMed Google Scholar
• Di Pino, A., Urbano, F., Piro, S., Purrello, F. & Rabuazzo, A. M. Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk. World J Diabetes 7, 423–432, doi:10.4239/wjd.v7.i18.423 (2016).
  Article PubMed PubMed Central Google Scholar
• Undas, A., Celinska-Lowenhoff, M., Lowenhoff, T. & Szczeklik, A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4, 1029–1036, doi:10.1111/j.1538-7836.2006.01882.x (2006).
  Article CAS PubMed Google Scholar
• Undas, A., Brummel-Ziedins, K. E. & Mann, K. G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 109, 2285–2292 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Knapp, M., Lisowska, A., Knapp, P. & Baranowski, M. Dose-dependent effect of aspirin on the level of sphingolipids in human blood. Adv Med Sci 58, 274–281, doi:10.2478/ams-2013-0021 (2013).
  Article CAS PubMed Google Scholar
• Manolis, A. S., Manolis, T. A., Papadimitriou, P., Koulouris, S. & Melita, H. Combined antiplatelet therapy: still a sweeping combination in cardiology. Cardiovasc Hematol Agents Med Chem 11, 136–167 (2013).
  Article CAS PubMed Google Scholar
• Mehta, S. R. Aspirin for prevention and treatment of cardiovascular disease. Ann Intern Med 150, 414–416 (2009).
  Article PubMed Google Scholar
• Angiolillo, D. J. & Ferreiro, J. L. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. Am J Cardiovasc Drugs 13, 233–250, doi:10.1007/s40256-013-0022-7 (2013).
  Article CAS PubMed Google Scholar
• Elblbesy, M. A., Hereba, A. R. & Shawki, M. M. Effects of aspirin on rheological properties of erythrocytes in vitro. Int J Biomed Sci 8, 188–193 (2012).
  CAS PubMed PubMed Central Google Scholar
• Gasparyan, A. Y., Ayvazyan, L., Pretorius, E. & Kitas, G. D. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des 20, 552–566 (2014).
  Article CAS PubMed Google Scholar
• Santos, M. T. et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 6, 615–621, doi:10.1111/j.1538-7836.2008.02915.x (2008).
  Article CAS PubMed Google Scholar
• Sostres, C., Gargallo, C. J. & Lanas, A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther 5, 40–49, doi:10.4292/wjgpt.v5.i1.40 (2014).
  Article PubMed PubMed Central Google Scholar
• Berk, M. et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11, 74, doi:10.1186/1741-7015-11-74 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Slyepchenko, A. et al. Intestinal dysbiosis, gut hyperpermeability and bacterial translocation: missing links between depression, obesity and type 2 diabetes? Curr Pharm Des (2016).
• Li, X. & Atkinson, M. A. The role for gut permeability in the pathogenesis of type 1 diabetes - a solid or leaky concept? Pediatr Diabetes 16, 485–492, doi:10.1111/pedi.12305 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Vaarala, O., Atkinson, M. A. & Neu, J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57, 2555–2562, doi:10.2337/db08-0331 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• de Kort, S., Keszthelyi, D. & Masclee, A. A. Leaky gut and diabetes mellitus: what is the link? Obes Rev 12, 449–458, doi:10.1111/j.1467-789X.2010.00845.x (2011).
  Article PubMed CAS Google Scholar
• Delzenne, N. M., Cani, P. D., Everard, A., Neyrinck, A. M. & Bindels, L. B. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia 58, 2206–2217, doi:10.1007/s00125-015-3712-7 (2015).
  Article CAS PubMed Google Scholar
• Schicho, R., Marsche, G. & Storr, M. Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets 16, 181–188 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Kitchens, R. L. & Thompson, P. A. Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins. J Endotoxin Res 9, 113–118, doi:10.1179/096805103125001504 (2003).
  Article CAS PubMed Google Scholar
• Kopp, F., Kupsch, S. & Schromm, A. B. Lipopolysaccharide-binding protein is bound and internalized by host cells and colocalizes with LPS in the cytoplasm: Implications for a role of LBP in intracellular LPS-signaling. Biochim Biophys Acta 1863, 660–672, doi:10.1016/j.bbamcr.2016.01.015 (2016).
  Article CAS PubMed Google Scholar
• Kam, J. H., Lenassi, E. & Jeffery, G. Viewing Ageing Eyes: Diverse Sites of Amyloid Beta Accumulation in the Ageing Mouse Retina and the Up-Regulation of Macrophages. Plos One 5, doi:10.1371/journal.pone.0013127 (2010).
• Ma, Y., Tao, Y., Lu, Q. & Jiang, Y. R. Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy. Am J Ophthalmol 152, 678–685 e672, doi:10.1016/j.ajo.2011.03.007 (2011).
  Article CAS PubMed Google Scholar
• Yoneda, S. et al. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 49, 106–108, doi:10.1007/s10384-004-0156-x (2005).
  Article CAS PubMed Google Scholar
• Gong, W. et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 72, 213–218, doi:10.1038/sj.ki.5002305 (2007).
  Article CAS PubMed Google Scholar
• Stettler, C. et al. Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Diabetes Care 32, 1098–1100, doi:10.2337/dc08-2137 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Khalighi, M. A., Dean Wallace, W. & Palma-Diaz, M. F. Amyloid nephropathy. Clin Kidney J 7, 97–106, doi:10.1093/ckj/sfu021 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, F. et al. Valsartan inhibits amylin-induced podocyte damage. Microvasc Res 106, 101–109, doi:10.1016/j.mvr.2016.04.007 (2016).
  Article CAS PubMed Google Scholar
• Shin, S. C. & Robinson-Papp, J. Amyloid Neuropathies. Mount Sinai Journal of Medicine 79, 733–748, doi:10.1002/msj.21352 (2012).
  Article PubMed PubMed Central Google Scholar
• Guan, J., Mishra, S., Falk, R. H. & Liao, R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol 302, H544–552, doi:10.1152/ajpheart.00815.2011 (2012).
  Article CAS PubMed Google Scholar
• Perfetto, F. et al. Cardiac amyloidosis: the heart of the matter. Intern Emerg Med 8, 191–203, doi:10.1007/s11739-011-0647-y (2013).
  Article PubMed Google Scholar